Calidi Biotherapeutics, Inc. (CLDI)
$0.90-5.26%Close
SELLCRISIS · day 72
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $7M
- Beta
- 1.33
- P/E (TTM)
- -0.02
- Short % float
- 4.24%
- Days to cover
- 1.0
- SI change
- +2.4%
- 1W
- -11.76%
- 1M
- -26.23%
- vs SPY 1W
- -11.63%
- vs SPY 1M
- -28.74%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 6
- VALUE
- 2
- GROWTH
- 39
- GARP
- 3
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-223.7%
REV YoY-
ROE-372.9%
EPS YoY-
ROA-242.5%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.02
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.41
P/FCF-
EV/EBITDA-0.01
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E61.99
ALTMAN Z-
CURR RATIO1.68
ND/EBITDA-
BETA1.33
Company news
FAQ
- What is LOPJLB’s current signal on CLDI?
- LOPJLB’s latest quantitative signal on Calidi Biotherapeutics, Inc. (CLDI) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CLDI in?
- Calidi Biotherapeutics, Inc. (CLDI) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Calidi Biotherapeutics, Inc. (CLDI) do?
- Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions…